Thrombolysis for acute ischemic stroke in the primary antiphospholipid syndrome

Journal of Rheumatology

Volumn 24, Issue 1, 1997, Pages 181-183

  Julkunen, Heikki ^a   Hedman, Christine ^b   Kauppi, Markku ^c  

^a PEIJAS HOSPITAL   (Finland)

^b PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

^c RHEUMATISM FOUNDATION HOSPITAL   (Finland)

Author keywords

antiphospholipid antibodies; stroke; thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CASE REPORT; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STROKE;

ADULT; ANTIPHOSPHOLIPID SYNDROME; CEREBROVASCULAR DISORDERS; FEMALE; HUMANS; INTRACRANIAL EMBOLISM AND THROMBOSIS; RECOMBINANT PROTEINS; RISK FACTORS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0031035998     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Hughes GRV, Harris EN, Gharavi AE: The anticardiolipin syndrome. J Rheumatol 1986;13:486-9.
2. Harris EN: Antiphospholipid antibodies. Br J Hematol 1990;74:1-9.
3. Asherson RA, Khamashta MA, Ordi-Ros J, et al: The primary antiphospholipid syndrome: Major clinical and serological features. Medicine 1989;68:366-74.
4. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV: The management of thrombosis in the antiphospholipid syndrome. N Engl J Med 1995;332:993-7.
5. Braune S, Siekmann R, Vaith P, Lücking CH: Primary antiphospholipid syndrome and cerebral ischemia: Report of acute intervention in two cases and literature review with emphasis on therapeutic options. Rheumatol Int 1993;13:169-74.
6. Muir KW, Squire IB, Alwan W, Lees KR: Anticardiolipin antibodies in an unselected stroke population. Lancet 1994;344:452-6.
7. Montalbam J, Codina A, Ordi J, Vilardell M, Khamashta MA, Hughes GRV: Antiphospholipid antibodies in cerebral ischemia. Stroke 1991;22:750-3.
8. Brey RL, Hart RG, Sherman DG, Tegeler CH: Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 1990;40:1190-6.
9. Hommel M, Boissel JP, Cornu C, et al for the MAST Study Group: Termination of trial of streptokinase in severe acute ischemic stroke. Lancet 1995;57:345.
10. Donnan GA, Davis SM, Chambers BR, et al: Trials of streptokinase in acute ischemic stroke. Lancet 1995;345:578-9.
11. Hacke W, Kaste M, Fieschi C, et al: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study. JAMA 1995;274:1017-25.
12. The National Institute of Neurological Disorders and Stroke rt-PA study group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
13. Rosove MH, Brewer PMC: Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992;117:303-8.
14. Jouhikainen T, Stephansson E, Leirisalo-Repo M: Lupus anticoagulant as a prognostic marker in systemic lupus erythematosus. Br J Rheumatol 1993;32:568-73.
15. Barbui T, Finazzi G: Clinical trials on antiphospholipid antibodies: What is being done and what is needed. Lupus 1994;3:303-1.